Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.
Saved in:
| Title: | Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin. |
|---|---|
| Authors: | Pointreau, Y.1 (AUTHOR) y.pointreau@ilcgroupe.fr, Larnaudie, A.2 (AUTHOR), Sun, X.S.3 (AUTHOR), Rolland, F.4 (AUTHOR), Boisselier, P.5 (AUTHOR), Tao, Y.6 (AUTHOR), Hugo, C.7 (AUTHOR), Bourhis, J.8 (AUTHOR) |
| Source: | Radiotherapy & Oncology. Jun2026, Vol. 219, pN.PAG-N.PAG. 1p. |
| Subjects: | Cetuximab, Head & neck cancer, Squamous cell carcinoma, Radiotherapy, Cisplatin, Apoptosis inhibition, Clinical trials, Adverse health care events |
| Abstract: | XXL was a placebo-controlled phase 3 evaluating cetuximab-radiotherapy and xevinapant (IAP inhibitor) in locally advanced squamous cell carcinoma of the head and neck, ineligible for cisplatin (Unfit). Following the unfavorable outcomes of Trilynx [1] , XXL the trial was prematurely discontinued after the enrollment of 19 patients and subsequently unblinded; the safety analysis then revealed an increase in treatment-related deaths with xevinapant. [ABSTRACT FROM AUTHOR] |
| Copyright of Radiotherapy & Oncology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: egs DbLabel: Engineering Source An: 194047314 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Pointreau%2C+Y%2E%22">Pointreau, Y.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> y.pointreau@ilcgroupe.fr</i><br /><searchLink fieldCode="AR" term="%22Larnaudie%2C+A%2E%22">Larnaudie, A.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sun%2C+X%2ES%2E%22">Sun, X.S.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rolland%2C+F%2E%22">Rolland, F.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Boisselier%2C+P%2E%22">Boisselier, P.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tao%2C+Y%2E%22">Tao, Y.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hugo%2C+C%2E%22">Hugo, C.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bourhis%2C+J%2E%22">Bourhis, J.</searchLink><relatesTo>8</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Radiotherapy+%26+Oncology%22">Radiotherapy & Oncology</searchLink>. Jun2026, Vol. 219, pN.PAG-N.PAG. 1p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Cetuximab%22">Cetuximab</searchLink><br /><searchLink fieldCode="DE" term="%22Head+%26+neck+cancer%22">Head & neck cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Squamous+cell+carcinoma%22">Squamous cell carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22Radiotherapy%22">Radiotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Cisplatin%22">Cisplatin</searchLink><br /><searchLink fieldCode="DE" term="%22Apoptosis+inhibition%22">Apoptosis inhibition</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Adverse+health+care+events%22">Adverse health care events</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: XXL was a placebo-controlled phase 3 evaluating cetuximab-radiotherapy and xevinapant (IAP inhibitor) in locally advanced squamous cell carcinoma of the head and neck, ineligible for cisplatin (Unfit). Following the unfavorable outcomes of Trilynx [1] , XXL the trial was prematurely discontinued after the enrollment of 19 patients and subsequently unblinded; the safety analysis then revealed an increase in treatment-related deaths with xevinapant. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Radiotherapy & Oncology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=194047314 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.radonc.2026.111479 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: N.PAG Subjects: – SubjectFull: Cetuximab Type: general – SubjectFull: Head & neck cancer Type: general – SubjectFull: Squamous cell carcinoma Type: general – SubjectFull: Radiotherapy Type: general – SubjectFull: Cisplatin Type: general – SubjectFull: Apoptosis inhibition Type: general – SubjectFull: Clinical trials Type: general – SubjectFull: Adverse health care events Type: general Titles: – TitleFull: Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pointreau, Y. – PersonEntity: Name: NameFull: Larnaudie, A. – PersonEntity: Name: NameFull: Sun, X.S. – PersonEntity: Name: NameFull: Rolland, F. – PersonEntity: Name: NameFull: Boisselier, P. – PersonEntity: Name: NameFull: Tao, Y. – PersonEntity: Name: NameFull: Hugo, C. – PersonEntity: Name: NameFull: Bourhis, J. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: Jun2026 Type: published Y: 2026 Identifiers: – Type: issn-print Value: 01678140 Numbering: – Type: volume Value: 219 Titles: – TitleFull: Radiotherapy & Oncology Type: main |
| ResultId | 1 |
